Shots:

• The PRIME designation is based on two Phase I/II studies in R/R cHL conducted at Baylor College of Medicine and the University of North Carolina Lineberger Comprehensive Cancer Center
• The studies showed the complete disappearance of tumors in ~60% of patients at the highest dose level with no serious toxicities- associated with several other CAR-T therapies. The results were published in Clinical Oncology
• The company plans to commence a multi-center pivotal study in the US during 2021. Additionally- P-I clinical study for patients with r/r CD30 positive NHL is open for enrollment in the US

 ­ Ref: PR Newswire | Image: PR Newswire